Characteristics of the study cohort of 691 chronic phase-chronic myeloid leukemia patients
| . | Period of diagnosis . | |||
|---|---|---|---|---|
| 1990-1994, n = 153 . | 1995-1999, n = 191 . | 2000-2007, n = 347 . | 1990-2007, n = 691 . | |
| Male sex (n,%) | 83 (54) | 112 (59) | 175 (50) | 370 (54) |
| Median age at diagnosis, y (range) | 55 (17-88) | 56 (16-89) | 57 (16-95) | 56 (16-95) |
| Age classes, y (n, %) | ||||
| 15-44 | 48 (31) | 58 (30) | 85 (24) | 191 (28) |
| 45-54 | 29 (19) | 30 (16) | 75 (22) | 134 (19) |
| 55-64 | 35 (23) | 43 (23) | 67 (19) | 145 (21) |
| 65-74 | 24 (16) | 42 (22) | 53 (15) | 119 (17) |
| 75 and older | 17 (11) | 18 (9) | 67 (19) | 102 (15) |
| Sokal score (n, %) | ||||
| Low | 53 (35) | 73 (38) | 120 (35) | 246 (36) |
| Intermediate | 47 (31) | 61 (32) | 135 (39) | 243 (35) |
| High | 34 (22) | 40 (21) | 72 (21) | 146 (21) |
| Unknown | 19 (12) | 17 (9) | 20 (6) | 56 (8) |
| Patients with imatinib, n, % | 28 (18) | 83 (43) | 323 (93) | 434 (63) |
| Patients with IFN, n, % | 91 (59) | 135 (71) | 98 (28) | 324 (47) |
| Patients treated by allogeneic stem cell transplantation | 29 (19) | 49 (26) | 22 (6) | 100 (14) |
| Life status at January 1, 2008 (n, %) | ||||
| Alive | 32 (21) | 80 (42) | 277 (80) | 389 (56) |
| Dead | 115 (75) | 103 (54) | 59 (17) | 277 (40) |
| Lost to follow-up | 6 (4) | 8 (4) | 11 (3) | 25 (4) |
| . | Period of diagnosis . | |||
|---|---|---|---|---|
| 1990-1994, n = 153 . | 1995-1999, n = 191 . | 2000-2007, n = 347 . | 1990-2007, n = 691 . | |
| Male sex (n,%) | 83 (54) | 112 (59) | 175 (50) | 370 (54) |
| Median age at diagnosis, y (range) | 55 (17-88) | 56 (16-89) | 57 (16-95) | 56 (16-95) |
| Age classes, y (n, %) | ||||
| 15-44 | 48 (31) | 58 (30) | 85 (24) | 191 (28) |
| 45-54 | 29 (19) | 30 (16) | 75 (22) | 134 (19) |
| 55-64 | 35 (23) | 43 (23) | 67 (19) | 145 (21) |
| 65-74 | 24 (16) | 42 (22) | 53 (15) | 119 (17) |
| 75 and older | 17 (11) | 18 (9) | 67 (19) | 102 (15) |
| Sokal score (n, %) | ||||
| Low | 53 (35) | 73 (38) | 120 (35) | 246 (36) |
| Intermediate | 47 (31) | 61 (32) | 135 (39) | 243 (35) |
| High | 34 (22) | 40 (21) | 72 (21) | 146 (21) |
| Unknown | 19 (12) | 17 (9) | 20 (6) | 56 (8) |
| Patients with imatinib, n, % | 28 (18) | 83 (43) | 323 (93) | 434 (63) |
| Patients with IFN, n, % | 91 (59) | 135 (71) | 98 (28) | 324 (47) |
| Patients treated by allogeneic stem cell transplantation | 29 (19) | 49 (26) | 22 (6) | 100 (14) |
| Life status at January 1, 2008 (n, %) | ||||
| Alive | 32 (21) | 80 (42) | 277 (80) | 389 (56) |
| Dead | 115 (75) | 103 (54) | 59 (17) | 277 (40) |
| Lost to follow-up | 6 (4) | 8 (4) | 11 (3) | 25 (4) |